Compare Global X CleanTech (CTEC) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X CleanTech vs Mesoblast Limited — how do they compare? Global X CleanTech trades at $55.45 (market cap $25.33M), while Mesoblast Limited trades at $13.8 (market cap $1.81B). The key difference: Mesoblast Limited is far larger — about 71.5× Global X CleanTech's market cap, and Mesoblast Limited is more actively traded (240,620 versus 2,662). Which is the better fit depends on your goals — on Pluang, investors hold Global X CleanTech for 42 Days and Mesoblast Limited for 14 Days on average.
| CTEC | MESO | |
|---|---|---|
Market Cap | $25.33M | $1.81B |
Volume | 2,662 | 240,620 |
Sector | Sector/Thematic | Health |
52-Week High | $78.11 | $20.96 |
52-Week Low | $50.82 | $13.19 |
Typical Hold Time | 42 Days | 14 Days |
Enterprise Value | — | $1.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X CleanTech
CTEC invests in companies at the forefront of the clean technology industry. It focuses on disruptive innovations in renewable energy production, energy storage, smart grids, and energy efficiency, with top holdings like Enphase and First Solar.
Read more on CTEC →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
